MODULE

2012-2013 Psychiatric Pharmacy Review Course Course Components (ACPE Only)

The 2012-2013 CPNP Psychiatric Pharmacotherapy Review Course (ACPE Only) includes the following:

2012-2013 Psychiatric Pharmacy Review Course - ACPE Credit Only

The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care.

Read more about this session.

Course Components

The APNA Endorsed CPNP Psychiatric Pharmacotherapy Review Course includes the following:

2012-2013 APNA Endorsed CPNP Psychiatric Pharmacotherapy Review Course

In cooperation with the American Psychiatric Nurses Association (APNA), the College of Psychiatric and Neurologic Pharmacists (CPNP) is pleased to offer the APNA endorsed CPNP Psychiatric Pharmacotherapy Review Course at CPNP member rates. This course is structured to provide knowledge- based education as defined in Accreditation Council for Pharmacy Education (ACPE) guidelines. The course examinations must be submitted by December 31, 2013.

APNA members can access this Accreditation Council for Pharmacy Education (ACPE) approved distance education course at CPNP member prices. Both a for-credit and no-credit (resource only) purchase option is being provided at a cost of $320 and $150 respectively. Non members of APNA can purchase the product for $480 (for-credit) and $150 (no-credit). The 20.0 contact hours of ACPE credit are accepted for American Nurses Credentialing Center Certification Renewal. You can preview a segment of a curriculum module and speaker presentation. Read on to learn more about this great APNA offer and register now.

Registration

Registration is closed. The new version of the course will be available mid-January 2014.

Accreditation (for-credit version only)

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2012-2013 APNA Endorsed Psychiatric Pharmacotherapy Review Course is a knowledge-based course and will provide up to 20 contact hours (2.0 CEUs) of continuing education credit.

Statements of Credit (for-credit version only)

Registrants can obtain up to 20.0 contact hours of ACPE credit by successfully completing the CPNP Psychiatric Pharmacotherapy Review Course online examinations for each of the 14 topic areas included in the course. The course expires December 31, 2013.

ACPE Statements of Credit will be available online at cpnp.org upon successful completion of each examination for the 14 topic areas contained in the course. Successful completion is defined as achieving a score of 60% or higher on each examination. Notification of statement availability will be provided upon successful completion of the examination.

NCCCN Neuropsychiatric Learning Program: Course Requirements

Access to and Completion of Modules

  1. All modules and presentations can be accessed at http://cpnp.org/ed/course/ncccn
  2. Each time you wish to access a module, you will be “purchasing” a course for free within the CPNP website.
  3. The first time you purchase a course, you will be required to complete a user profile on the CPNP system and your initial access request must be approved by Genoa which might result in a slight delay.

Genoa Neuropsychiatric Pharmacy Modules: Course Requirements

Access to and Completion of Modules

  1. All modules and presentations can be accessed at http://cpnp.org/ed/course/genoa
  2. Each time you wish to access a module, you will be “purchasing” a course for free within the CPNP website.
  3. The first time you purchase a course, you will be required to complete a user profile on the CPNP system and your initial access request must be approved by Genoa which might result in a slight delay.

Genoa Neuropsychiatric Pharmacy Learning Module: Substance Abuse

At the end of this program, the participant should be able to:

  1. Identify signs and symptoms of acute intoxication, acute withdrawal, and chronic dependency associated with the use of the following drugs of abuse:
    1. Alcohol
    2. Opiates (pain medications, heroin)
    3. Nicotine
    4. Cocaine
    5. Stimulants (Methamphetamines)
    6. Inhalants
    7. Marijuana
  2. Describe the pharmacologic properties and pharmacokinetic parameters for drug therapies used in the treatment of substance use disorders.
  3. Select appropriate pharmacotherapy (agent, dose, duration of therapy) for substance use disorders based on current practice guidelines.
  4. Develop a monitoring plan that includes assessment of efficacy, and evaluation for adverse effects, drug interactions, and toxicity given a patient undergoing treatment for a substance use disorder,
  5. Compose a management strategy given a specific drug-related problem in a patient with a substance use disorder.
  6. Develop a plan to provide appropriate patient education for substance use disorders
Read more about this session.

Genoa Neuropsychiatric Pharmacy Learning Module: Sleep Disorders

At the end of this program, the participant should be able to:

  1. Outline a comprehensive clinical assessment of patient sleep complaints.
  2. Design an individualized treatment plan for patients of different ages and psychiatric diagnoses with sleep complaints.
  3. Assess an individual’s clinical presentation and the appropriateness of drug therapy to treat periodic limb movements during sleep (PLMS), restless legs syndrome, obstructive sleep apnea, or narcolepsy.
  4. Given an individual patient’s type of insomnia, justify the decision to prescribe one hypnotic over another for the management of chronic insomnia.
  5. Given an individual patient’s sleep disorder diagnoses and drug therapy regimen, judge the safety of that regimen after screening for drug interactions, appropriate dose and timing of medication administration, and duration of treatment.
  6. Identify the use of accurate information and optimal language for counseling a patient on the safe and effective use of hypnotic medication to manage sleep complaints.
Read more about this session.

Genoa Neuropsychiatric Pharmacy Learning Module: Schizophrenia

At the end of this program, the participant should be able to:

  1. Evaluate within a case example whether the patient meets DSM-IV-TR criteria for schizophrenia, schizoaffective disorder, schizophreniform, brief reactive psychosis, or substance-induced psychotic disorder.
  2. Analyze the appropriateness and results of commonly used rating scales for the evaluation and management of schizophrenia.
  3. Differentiate among all antipsychotics with regards to efficacy, adverse reactions, dosing, and monitoring.
  4. Design a monitoring plan for patients on antipsychotic medications for movement disorders using appropriate rating scales.
  5. Compare and contrast the various treatment guidelines for the management of schizophrenia.
  6. Assess the use of antipsychotics in special populations (e.g., treatment refractory, pregnancy/lactation).
  7. Solve drug therapy problems in patients with schizophrenia and/or movement disorders through the provision of appropriate patient education.
Read more about this session.

Genoa Neuropsychiatric Pharmacy Learning Module: Pediatrics and Developmental Disorders

At the end of this program, the participant should be able to:

  1. Evaluate whether a child’s clinical presentation meets diagnostic criteria for:
    1. Attention-deficit/ hyperactivity disorder
    2. Tourette’s disorder/ tic disorders
    3. Conduct disorder / oppositional-defiant disorder
    4. Separation anxiety disorder.
  2. Given a case example of a child with any of the above conditions, discriminate among drug treatments to select the most effective and safe option with an appropriate dose and schedule.
  3. Develop an optimal plan to monitor for adverse effects of psychostimulants, antipsychotics, antidepressants, mood stabilizers, and anxiolytics in children and adolescents.
  4. Resolve psychotropic drug therapy problems in children and adolescents by modifying the pharmacotherapeutic treatment plan and providing appropriate patient and family counseling.
  5. Distinguish between the behavioral phenotypes and the major medical complications of the following syndromes:
    1. Autistic Disorder
    2. Asperger's Disorder
    3. Down Syndrome
    4. Prader-Willi Syndrome
    5. Fragile X Syndrome
    6. Klinefelter’s Syndrome
    7. Rett’s Disorder.
  6. Discuss risk factors, pathogenesis, clinical course, and appropriate drug treatment options of the above syndromes.
  7. Identify special considerations for treating the following problems in an individual with mental retardation and/or developmental disorder:
    1. Self-injurious behavior
    2. Mood disorders
    3. Anxiety disorders
    4. Psychotic disorders.
  8. Describe the limitations of the published literature on psychiatric drug treatment in people with developmental disorders.
Read more about this session.